EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 166 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $231,000 | -8.3% | 5,428 | +3.4% | 0.01% | -14.3% |
| Q2 2020 | $252,000 | +15.1% | 5,248 | +10.1% | 0.01% | -12.5% |
| Q1 2020 | $219,000 | -23.2% | 4,768 | +0.4% | 0.01% | 0.0% |
| Q4 2019 | $285,000 | +11.3% | 4,748 | +5.1% | 0.01% | +14.3% |
| Q3 2019 | $256,000 | +2.8% | 4,518 | +0.9% | 0.01% | 0.0% |
| Q2 2019 | $249,000 | -2.7% | 4,478 | -11.8% | 0.01% | 0.0% |
| Q1 2019 | $256,000 | +26.7% | 5,078 | +1.2% | 0.01% | +16.7% |
| Q4 2018 | $202,000 | -18.9% | 5,018 | +39.9% | 0.01% | 0.0% |
| Q3 2018 | $249,000 | -0.8% | 3,588 | +8.1% | 0.01% | -14.3% |
| Q2 2018 | $251,000 | – | 3,318 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |